Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Impact of ADCs on the treatment landscape of UC

Daniel Petrylak • 17 Feb 2022
GU Cancers 2022
Bladder Cancer Genitourinary Cancer Antibodies Enfortumab vedotin

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, provides an overview of the impact of antibody-drug conjugates (ADCs) on the treatment landscape of patients with urothelial carcinoma, including the use of enfortumab vedotin. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Daniel Petrylak

0:43
Current developments in FGFR inhibitors for urothelial cancer
Daniel Petrylak • 3 Jun 2023
1:59
How can we best sequence novel treatments in urothelial cancer?
Daniel Petrylak • 3 Jun 2023
0:24
HER2-targeting ADCs for urothelial carcinoma
Daniel Petrylak • 3 Jun 2023
1:04
THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations
Daniel Petrylak • 3 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals